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Introduction
Gaucher Disease (GD) is an inherited metabolic disorder of lysosomal storage 
disease (LSDs) occurred by deficient activity of the glucocerebrosidase (GBA) 
(1). According to central nervous system symptoms, GD is classified into three 
main types including: Type I of the GD (OMIM 230800) or non-neuronopathic 
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Chitotriosidase (CT) activity is a useful biomarker for diagnosis and monitoring 
of Gaucher disease (GD). Its application is limited by some variants in the CT 
gene. Two main polymorphisms are 24 bp duplication and G102S led to reduce 
CT activity. The aim of this study was to determine these variants influencing 
on plasma CT activity.
Materials & Methods 
Blood samples were collected from 33 patients with GD, 15 sibling carriers and 
105 healthy individuals serving as controls. CT activity was measured using 
4-methylumbelliferyl-β-D-N,N′,N″triacetylchitotrioside substrate in plasma 
samples. The CT genotypes of 24 bp duplication and G102S variants were 
determined using PCR and PCR-RFLP.
Results
Untreated GD patients had a significantly higher CT activity compared to treated 
patients (P = 0.021). In addition, chitotriosidase activity in carriers was higher 
rather than controls. Allele frequencies of 24 bp duplication in GD patients, 
sibling carriers and controls were 0.21, 0.266 and 0.29 and for G102S were 0.318, 
0.366 and 0.219, respectively. Different G102S genotypes had not significant 
effect on CT activity. Chitotriosidase activity has a positive correlation with 
age in normal group, carriers, and negative correlation with hemoglobin in GD 
patients. Using cut-off level of 80.75 nmol/ml/h, sensitivity and specificity of 
CT activity were 93.9% and 100%, respectively.
Conclusion
Chitotriosidase activity is a suitable biomarker for diagnosis and monitoring of 
GD. Determination of 24 bp duplication is helpful for more accurate monitoring 
the GD patient’s therapy. However, it seems that, specifying of the G102S 
polymorphism is not required for Iranian GD patients.
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patient CT genotypes is important to correlate the 
plasma CT activity with disease severity for therapeutic 
monitoring. 
The aim of present study was to report the CT activity 
and frequency of the Dup 24 and G102S missense 
mutation in Iranians GD patients, obligate carriers and 
normal population. Especially, this analyte changes 
in response to treatment and would be useful to 
individualize dose.
Materials & Methods 
Samples
We conducted our study on 33 GD patients and 15 
sibling carriers approved by PCR-RFLP or sequencing 
method. Four of patients had GD type III and referred to 
Mofid Children’s Hospital and Ali-Asghar Children’s 
Hospital of Tehran, Iran. All patients were previously 
diagnosed with GD according to fluorometric assay of 
the GBA activity, having the gaucher cells in the bone 
marrow or GBA gene analysis (unpublished data). 
Twenty-one of them received Cerezyme therapy as 
average intravenous injection dose: 30-60 U/kg per 2 
weeks. The average time of ERT was 4.05 ± 1.87 yr. 
Moreover, we selected an age and sex matched group 
of 105 normal individuals as controls. 
Informed written consent was obtained from individuals 
or their parents before participation. This study was 
approved by Ethics Committee of Tarbiat Modares 
University and Pasteur Institute of Iran.
The characteristics of studied subjects are shown in 
Table 1. Three ml peripheral blood was collected 
from each subject, mixed with EDTA, and then 65 μl 
aliquots were spotted on Whatman 903 filter paper and 
dried at room temperature. Finally, blood spot, plasma 
and cell pellets kept at −80 °C until time of analysis. In 
addition, cell blood count (CBC) was measured by a 
hematology analyzer (Sysmex, Japan).
Fluorimetry Assays
GBA activity was determined on dry blood spot sample 
by a modified method (13). Chitotriosidase in plasma 
was measured based on the method of Hollak et al. 
(14). Briefly, 5 µl of plasma (in the case of GD, 1 to 
50 diluted with water) was mixed with 100 μL of 0.022 
mmol/L 4MU-chitotrioside (Sigma-Aldrich Co, USA) 
form associated with organomegaly, anemia and 
thrombocytopenia, Type II (OMIM 230900) or acute 
neuronopathic disease and Type III (OMIM 231000) 
of the GD or chronic neuronopathic form of the disease 
manifested: seizure, supranuclear horizontal gaze 
palsy or other eye symptoms, and mental retardation. 
Generally, GD is diagnosed by measurement of 
β-glucosidase activity in leukocytes and fibroblasts or 
by genetic testing of GBA gene as confirmatory test 
(1-3).
In addition, several serum analytes have been described 
for monitoring GD including pulmonary and activation-
regulated chemokine (PARC/CCL18), angiotensin-
converting enzyme (ACE), macrophage inflammatory 
proteins (MIP)-1α, MIP-1β, CD163 and etc. (1, 4-6). 
However, these are moderately increased but, non-
specific to this disease (5-6). Now, the most powerful 
biomarker for monitoring of GD is chitotriosidase (CT; 
EC 3.2.1.14) (5-7), an enzyme secreted in plasma by 
activated macrophages from different tissues (7). Its 
activity is highest in untreated Type 1 GD patients, 
which is averagely 600-fold greater than that in 
controls and correlated with disease severity. Note 
that, plasma CT levels gradually decreased during ERT 
(enzyme replacement therapy). Therefore, it is useful 
for monitoring disease severity and the effectiveness of 
therapy in GD (6).
Besides, CT is useful on the clinical management of 
GM1-gangliosidosis (8), Alzheimer, amyotrophic 
lateral sclerosis, atherosclerosis, β-thalassemia and 
malaria (9-11).
The CT gene (MIM 600031) is located on the 
chromosome 1q31-q32 and consists of 12 exons (12). 
A recessive inherited mutation of CT gene, which 
consists of c.1049_1072dup24 or 24bp duplication 
(Dup24) in exon 10, encodes inactive CT protein lacks 
the 29 amino acids and results in an inactive enzyme 
(3). About 6% of Caucasians are homozygous and 
30% to 40% are heterozygous for the Dup24 null 
allele (6). Another common polymorphism, p.G102S 
(Glycine 102 Serine), interferes with CT catalytic 
properties when using 4-methylumbelliferyl-β-D-N, 
N′, N″triacetylchitotrioside (4MU-chitotrioside), 
causing activity reduction of CT levels and consequent 
misinterpretation (5). Thus, determination of GD 
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agarose gel.
Statistical Analysis
Data were analyzed using SPSS 16.0 (Chicago, IL, 
USA) and GraphPad Prism 6 software. The normality 
of variables was tested by Kolmogrov-Smirnov test. 
Continuous data were analyzed by Independent t-test 
or Mann–Whitney test, and Kruskal-wallis or ANOVA 
test. To evaluate the degree of linear association between 
different variables, Pearson or spearman correlation 
coefficients were calculated. The genotypes and allele 
frequencies of Dup24 and G102S variations between 
groups were compared using the Chi-square analysis. 
The level of significance was set at P<0.05. Finally, the 
clinical performances of CT activity for GD measured 
using receiver operating characteristic (ROC) curves. 
Cut-off value that provided the best combination of 
sensitivity and specificity was determined.
Results
Characteristics and the laboratory data of three main 
groups are presented in the Table 1. All groups in terms 
of age and sex were matched. As expected, significant 
differences in plasma CT activity values were found 
in patients with GD (9061 ± 11031) compared to the 
normal subjects (15.7 ± 11.5, P<0.001) or sibling 
carriers (25.8 ± 14.9, P<0.001). Particularly, GD 
treated with ERT (5827 ± 8288) had significant lower 
levels of CT activity than those were untreated (14719 
in McIlvain’s buffer (100mmol-1 citric acid and 200 
mmol-1 sodium phosphate, pH 5.2) and incubated 
at 37 °C for 30 min at dark place. The reaction was 
stopped with 1395µl of 0.2 M Na2CO3/glycine pH 
10.5. Fluorescence activity was measured by RF-5000, 
Shimadzu, Japan (Excitation 366 nm, Emission 448 
nm).
Enzyme activities were calculated based on a 
calibration curve of 4-methylumbelliferone (4-MU) for 
each assay.
CT genotyping
DNA was extracted by phenol-chloroform method 
(15). Briefly, the PCR amplification of both targets 
was carried out using previously described protocols 
(16, 17). For 24 bp duplication genotyping (16), prod-
ucts separated on 2.5% agarose gel. The presence of 
duplication in both alleles (Dup24/Dup24; Homozy-
gous) genotype produces only a 99bp fragment, wild 
genotype (Wt/Wt), produced a 75bp fragment. The 
presence of both 99 and 75bp fragments showed Wt/
Dup24 genotype (Heterozygote).
The G102S mutation genotyping was performed by 
PCR product (259bp) digestion with HpaII restric-
tion enzyme (Thermo Scientific™). Digestion yielded 
three bands including 259 or 240 and 19bp (17). In the 
presence of mutation, 259bp band remain intact. The 
wild type allele renders two bands of 240 and 19bp. 
Finally, digested products were separated on 3.5% 
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Table1. Characteristics of the study population
Parameter GD Patients (n=33) Controls (n=105) Sibling Carriers (n=15) P value
Sex (male%) 14 (42.4%) 51 (48.6%) 9 (60%) 0.082
Age (years) 11.5 ± 8.1 9.9 ± 6.6 14.33 ± 8.6 >0.05
GBA (µmol/lit/h) 0.63 ± 0.38 3.47 ± 0.90 2.15 ± 0.44 <0.001
CT (nmol/ml/h) 9061 ± 11031 15.7 ± 11.5 25.8 ± 14.9 <0.001
WBC (×103/µl) 6.07 ± 1.96 6.99 ± 1.63 6.96 ± 2.32 0.014
RBC (×106/µl) 4.51 ± 0.70 5.09 ± 0.41 5.16 ± 1.01 <0.001
Hemoglobin (g/dl) 12.17 ± 2.29 14.05 ± 1.41 15.09 ± 3.31 <0.001
Platelet (×103/µl) 154.03 ± 63.09 273.22 ± 69.12 245.33 ± 68.4 <0.001
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correlations. The Dup 24 genotypes distribution of GD 
patients, sibling carriers and controls are stated in Table 
2. All patients, carriers and controls with no detectable 
CT activity were homozygous for the 24bp variation. 
CT activity in three main groups and sub-groups are 
shown in Figure 1.
The G102S genotypes distribution of GD patients, 
sibling carriers and controls are stated in Table 2. 
± 13199, P=0.021), and patients with type III of disease 
insignificantly had a higher CT activity (14773 ± 
16108) than those with GD type I (8273 ± 10294).
According to Table 2, absence of CT activity was 
detected in two out of the 33 GD patients (6.1%), one out 
of carriers (7.7%), and 11 out of 105 control individuals 
(10.5%). These individuals were excluded from the 
statistical analysis concerning plasma CT activity and 
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A- Wt/Wt (Wild) 21 (63.6) 10593 ± 11389 55 (52.4) 22.2 ± 10.7a 8 (53.3) 34.06 ± 14.4a
B- Wt/24Dup (Hetero) 10 (30.3) 7654 ± 10886 39 (37.1) 11.2 ± 6.9 6 (40) 19.25 ± 6.67
C- 24Dup/24Dup 
(Homo)
2 (6.1) 0 11 (10.5) 0 1 (6.7) 0
24Dup allele (%) 14 (21.2) - 61 (29.04) - 8 (26.6) -
G102S genotypes
D- GG (Wild) 17 (51.5) 6935 ± 9585 64 (61) 16.3 ± 11.4 7 (46.6) 28 ± 11.4
E- GA (Hetero) 11 (33.3) 11589 ± 3490 36 (34.3) 14.7 ± 11.9 6 (40) 23.8 ± 20.3
F- AA (Homo) 5 (15.2) 10723 ± 15190 5 (4.8) 15.9 ± 11.2 2 (13.4) 24.5 ± 14.8
G- GA+AA 16 (48.5) 11318 ± 12290 41 (39.04) 14.9 ± 11.7 9 (60) 24 ± 18.1
A allele (%) 21 (31.8) - 46 (21.9) - 10 (33.3) -
Haplotypes
H- Both Wild (Ref) 8 (24.2) 10610 ± 13110 32 (30.5) 23.6 ± 9.4 5 (33.3) 31 ± 11.4
I- 24Dup/Wt – GG 7 (21.2) 4717 ± 2163 23 (21.9) 12.3 ± 2.9b 2 (13.3) 20.5 ± 10.6
J- Wt/Wt – GA 8 (24.2) 10494 ± 8175 20 (19) 20.02 ± 12.8 2 (13.3) 41.2 ± 27.9
K- 24Dup/Wt – GA 3 (9.1) 14509 ± 20459 14 (13.3) 9.6 ± 6.6c 4 (26.6) 20.1 ± 6.2
L- Wt/Wt – AA 5 (15.1) 10723 ± 15190 3 (2.8) 20.3 ± 9.7 1 (6.7) 35
M- 24Dup/Wt – AA 0 (0) - 2 (1.9) 9.2 ± 13.1 0 (0) -
 a; Statistically significant comparison between row A and B in controls (p<0.001) and in carriers (p=0.039) b; Statistically significant 
compared to H (reference group), in controls (p<0.001). c; Statistically significant to H, in control group (p<0.001).
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Furthermore, untreated patients with Wt/Wt genotype 
(n=7, 22255 ± 4715) had a higher CT activity than those 
with Wt/Dup24 genotype (n=4, 5212 ± 1506, P=0.014). 
Yet, reduced CT activities in G102S haplotypes 
containing mutant alleles were inconsistent and non-
significant (Table 2).  CT activity in control group, had 
a significant positive correlation with age (r=0.314, 
P<0.01). On the other hand, in GD patients negative 
correlation between CT activity and RBC number 
(r=-0.382, P<0.05) and hemoglobin concentration (r=-
0.580, P<0.001) was found. Moreover, in the anemic 
GD patients (n=19), CT activity was significantly 
higher (14141 ± 13109) than those without anemia 
(3662 ± 3994; P<0.01; Figure 1).
The area under ROC curve (AUC) was 0.943 for CT 
activity (Standard Error: 0.039). Diagnostic cut-off 
levels with the optimum sensitivity and specificity 
calculated from the ROC curve was CT >80.75 nmol/
ml/h. Using this optimum cut-off level, CT had 93.9% 
sensitivity, and 100% specificity. Likewise, positive 
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Fig 1: Chitotriosidase activity for GD patients and controls according to 
ERT, GD type, Dup24 and G102S genotypes.
Fig 2: ROC curve for CT activity (AUC= area under curve)
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this ratio among our controls and carriers, similar to 
different studies is about 2-fold (18, 26). Probably, the 
higher ratio observed, could be attributed to the small 
sample size (n=12) and selection bias, as there were 
eight related individuals among our GD patients. As 
well as, among different haplotypes of controls and 
sibling carriers, three sub-groups (I, K, and M rows of 
controls in Table 2) who had at least an allele of Dup24 
had a significant lower CT activity than reference group 
(row H in table 2).
Remarkably, our results showed that CT levels were 
not different in three genotypes of G102S variation or 
haplotypes contain mutant allele in patients, carriers or 
controls, and when CT activity were analyzed in treated 
or untreated GD patients, separately. Our finding is 
in line with results of Lee et al. (23) who examined 
the G102S allele frequency of subjects of European, 
Asian and African ancestry compared to enzyme 
activity. This finding differs from an investigation (6), 
which demonstrated that using 4-MU-chitotrioside as 
substrate, in vitro expression of the G102S alleles had 
23% of wild-type CT catalytic efficiency. As well, in 
another study (25), at a non-saturating concentration 
of 4-MU–chitotrioside, the catalytic efficiency of 
recombinant Serine102 CT was 70% that of wild-type 
Glycine102 measured.
Like to another study (27), we found a significant 
elevated CT activity in sibling carriers rather than 
controls (P=0.007). Possibly, in carrier’s subjects a 
small macrophage activation enhanced CT production. 
Besides, GD carriers had lower HDL- cholesterol 
compared to health individuals (28). Interestingly, 
hypoalphalipoproteinemia is due to enhanced activation 
of macrophages (29).
In our study, after adjusting the CT Dup 24 genotype, 
GD type III patients had an insignificantly higher mean 
of CT activity than GD type I patients. Like us, Ries et 
al. (30), reported that CT levels was higher in GD type 
III than in GD type I.
We found a positive correlation of CT activity and 
age both in controls (r=0.314, P<0.01) and carriers 
(r=0.479, P=0.08). Consistent to our result, Kurt 
et al. (31) revealed that, elder persons had a higher 
CT activity than youths. This phenomenon could 
be explained by the beginning of macrophage lipid 
predictive values (PPV), negative predictive value 
(NPV) were 100% and 98.03%, respectively.
Discussion
This is the first study conducted on an Iranian 
population, which describes the impact of Dup24 and 
G102S in the CT gene on GD patients, sibling carriers 
and normal population. We found that CT activity 
in untreated GD patients is significantly higher than 
normal population in accordance with previous studies 
(4-8). In our study, CT activity of treated and untreated 
patients compared to controls was about 371 and 937 
times higher, respectively. Nevertheless, two studies in 
Brazil reported increasing of about 176 (treated GD) 
and 600 (untreated GD) fold CT levels (8, 18). On the 
other hand, it is possible that, a higher CT level in our 
patients is due to ethnicity difference. As well, there is 
a report that shows average close to a thousand-fold CT 
elevated in symptomatic untreated non-neuronopathic 
GD patients (19). According to International 
Collaborative Gaucher Group (ICGG) and different 
studies recommendation, plasma CT activity declined 
during ERT and could be serve as indirect measurement 
of GD severity (6, 20, 21). Hence, specifying the CT 
gene mutations that affects plasma enzyme activity is 
helpful for use to assess GD patients.
The allele frequencies of Dup 24 in our GD patients, 
carriers and controls were 0.21, 0.26 and 0.29, 
respectively. The allele frequency of Dup 24 was 
reported between zero (22) in South Africa to more 
than 0.50 in Korea, China and Japan normal population 
(23, 24). It has also been reported an allele frequency 
0.22, 0.43, 0.20 in Spanish, Brazilian, and Dutch GD 
patients, respectively (5, 18, 25).
We determined the G102S allele frequencies in GD 
patients, carriers and controls as 0.32, 0.33 and 0.22, 
respectively (Table 2). In different populations, allele 
frequencies were 0.24, 0.26, and 0.27 in Asian, African, 
and European normal subjects, respectively (23). 
Similarly, G102S allele in GD patients was common as 
0.27, 0.31, and 0.24 in Spanish, Ashkenazi Jewish and 
Dutch ethnicity, respectively (5, 6, 25).
Interestingly, in untreated GD patients, CT activity 
in wild (Wt/Wt) genotypes was about 4-fold higher 
than those with heterozygote genotype. By contrast, 
Chitotriosidase Activity and Gene Polymorphism in Iranian Patients with Gaucher Disease and Sibling Carriers
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